CUAMC
RNAM

China Universal Asset Management Company’s Avidity Biosciences RNAM Stock Holding History

China Universal Asset Management Company’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,553
Closed -$1.77M – 519
2025
Q4 		$1.77M Buy
24,553
+2,002
+9% +$129K 0.14% 122
2025
Q3 		$983K Sell
22,551
-1,659
-7% -$67.1K 0.08% 181
2025
Q2 		$688K Buy
24,210
+97
+0.4% +$2.89K 0.06% 217
2025
Q1 		$712K Sell
24,113
-1,185
-5% -$36.9K 0.07% 212
2024
Q4 		$736K Buy
25,298
+2,772
+12% +$116K 0.07% 202
2024
Q3 		$1.03M Buy
22,526
+11,291
+100% +$490K 0.11% 135
2024
Q2 		$459K Sell
11,235
-4,064
-27% -$117K 0.06% 153
2024
Q1 		$390K Buy
15,299
+6,729
+79% +$105K 0.05% 206
2023
Q4 		$77.6K Buy
8,570
+6,675
+352% +$44.6K 0.02% 316
2023
Q3 		$12.1K Buy
1,895
+967
+104% +$8.33K ﹤0.01% 337
2023
Q2 		$10.3K Sell
928
-31
-3% -$389 ﹤0.01% 315
2023
Q1 		$14.7K Buy
959
+406
+73% +$8.93K 0.01% 250
2022
Q4 		$12.3K Buy
553
+65
+13% +$969 ﹤0.01% 208
2022
Q3 		$8K Buy
+488
New +$9.34K ﹤0.01% 229

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

China Universal Asset Management Company's RNAM Position: Q1 2026 in Review

China Universal Asset Management Company sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 24,553 shares — an estimated $1.77M sold.

China Universal Asset Management Company first reported a position in RNAM in Q3 2022 and held it in 14 quarters. The position peaked at $1.77M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • China Universal Asset Management Company reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • China Universal Asset Management Company sold 24,553 Avidity Biosciences shares in Q1 2026, an estimated $1.77M.
  • China Universal Asset Management Company first reported a position in Avidity Biosciences in Q3 2022 and held it in 14 quarters.
  • China Universal Asset Management Company's Avidity Biosciences position peaked at $1.77M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.